高级检索+

生物技术药物防护放射性雄性生殖损伤研究新进展

New advances in research on biotechnological drugs for preventing radiation-induced male reproductive injury

  • 摘要: 放射性雄性生殖损伤是盆腔肿瘤放疗后的一种并发症,在核事故及辐射事故时也可发生,主要表现为生殖器官结构和功能的破坏,严重者可导致终生不育。传统抗辐射药物因治疗窗口较窄和副作用较大等原因限制了其实际应用。生物技术药物具有靶向性较强,副作用较小等优点,在放射损伤防护中逐渐得到重视。本文综述了放射性雄性生殖损伤的分子机制、生物技术药物防护机制及相关前沿药物研究进展,旨在为放射性雄性生殖系统损伤的防护提供新思路。

     

    Abstract: Radiation-induced male reproductive injury is a complication of pelvic tumor radiotherapy,which can also occur in nuclear and radiation accidents. It mainly manifests as damage to the structure and function of reproductive organs, and in severe cases, can lead to lifetime infertility. Traditional antiradiation drugs face limitations in practical application owing to their narrow treatment windows and significant side effects. In contrast,biologics are gradually gaining attention for radiation injury protection due to their high specificity and relatively minimal side effects.This article reviews the molecular mechanisms of radiation-induced male reproductive injury, the protective mechanisms of biotechnological drugs, and the research progress of related cutting-edge drugs, aiming to provide new ideas for the protection of radiation-induced male reproductive system injury.

     

/

返回文章
返回